Artelo biosciences to present important new preclinical data on art12.11 at the 4th annual med-cannabis 2023 conference in germany

Solana beach, calif., nov. 30, 2023 (globe newswire) -- artelo biosciences, inc. (nasdaq: artl), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, and neurological conditions, today announced george warren, phd., principal scientist at artelo biosciences, will be presenting new preclinical data on art12.11, the company's proprietary cocrystal of cannabidiol (cbd) and tetremethylpyrazine (tmp), at the 4th annual med-cannabis 2023 conference being held december 4-5, 2023 in frankfurt, germany.
ARTL Ratings Summary
ARTL Quant Ranking